Aquestive Drug Patent Portfolio

Aquestive owns 3 orange book drugs protected by 5 US patents Given below is the list of Aquestive's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11273131 Pharmaceutical compositions with enhanced permeation 18 Jun, 2038
Active
US9095577 Stabilized amine-containing actives in oral film compositions 13 Jul, 2030
Active
US8580830 Non-mucoadhesive film dosage forms 23 Nov, 2029
Active
US8603514 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions 03 Apr, 2024 Expired
US8765167 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions 20 Feb, 2024 Expired


Given below is the list of recent legal activities going on the following drug patents of Aquestive.

Activity Date Patent Number
Patent litigations
7.5 yr surcharge - late pmt w/in 6 mo, Small Entity 27 Oct, 2021 US8580830
Payment of Maintenance Fee, 8th Yr, Small Entity 27 Oct, 2021 US8580830
Maintenance Fee Reminder Mailed 05 Jul, 2021 US8580830
Payment of Maintenance Fee, 8th Year, Large Entity 08 Jun, 2021 US8603514 (Litigated)
Email Notification 07 Apr, 2021 US8580830
Change in Power of Attorney (May Include Associate POA) 07 Apr, 2021 US8580830
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 06 Apr, 2021 US8580830
Correspondence Address Change 05 Apr, 2021 US8580830
Request for Trial Denied 20 Oct, 2017 US8603514 (Litigated)
Termination or Final Written Decision 06 Oct, 2017 US8603514 (Litigated)
Petition Requesting Trial 12 Jun, 2017 US8603514 (Litigated)
Petition Requesting Trial 09 Jun, 2017 US8603514 (Litigated)
Request for Trial Granted 12 May, 2017 US8603514 (Litigated)
Request for Trial Denied 05 Dec, 2016 US8603514 (Litigated)
Petition Requesting Trial 04 Nov, 2016 US8603514 (Litigated)


Aquestive's Drug Patent Litigations

Aquestive's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 28, 2014, against patent number US8765167. The petitioner BioDelivery Sciences International, Inc., challenged the validity of this patent, with MonoSol Rx, LLC. as the respondent. Click below to track the latest information on how companies are challenging Aquestive's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8603514 June, 2017 Terminated-Denied
(20 Oct, 2017)
MonoSol Rx, LLC Par Pharmaceutical, Inc.
US8603514 June, 2017 Terminated-Denied
(20 Oct, 2017)
MonoSol Rx, LLC Dr. Reddy’s Laboratories, Inc.
US8603514 November, 2016 Terminated-Settled
(06 Oct, 2017)
MonoSol Rx, LLC et al. Mylan Technologies, Inc. et al.
US8603514 May, 2016 Terminated-Denied
(05 Dec, 2016)
MonoSol Rx, LLC Dr. Reddy's Laboratories, Inc.
US8603514 December, 2015 Terminated-Denied
(23 May, 2016)
MONOSOL RX LLC Teva Pharmaceuticals USA Inc
US8765167 October, 2014 FWD Entered
(24 Mar, 2016)
MonoSol Rx, LLC. BioDelivery Sciences International, Inc.
US8765167 October, 2014 Terminated-Settled
(24 Mar, 2016)
MonoSol Rx, LLC. et al. BioDelivery Sciences International, Inc.
US8765167 October, 2014 Terminated-Denied
(20 May, 2015)
MonoSol Rx, LLC. BioDelivery Sciences International, Inc.


Aquestive Drug Patents' Oppositions Filed in EPO

Aquestive drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 11, 2012, by Lts Lohmann Therapie-Systeme Ag. This opposition was filed on patent number EP02801042A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11157819A Jun, 2014 Ahrens, Gabriele Patent maintained as amended
EP02782151A Jun, 2013 Acino Pharma AG Revoked
EP02782151A Jun, 2013 Germann, Sandra Revoked
EP02801042A Sep, 2012 Ahrens, Gabriele Patent maintained as amended
EP02801042A Sep, 2012 LTS LOHMANN Therapie-Systeme AG Patent maintained as amended


Aquestive's Family Patents

Aquestive drugs have patent protection in a total of 23 countries. It's US patent count contributes only to 46.8% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Aquestive Drug List

Given below is the complete list of Aquestive's drugs and the patents protecting them.


1. Exservan

Exservan is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8603514 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions 03 Apr, 2024
(7 months ago)
Expired
US8765167 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions 20 Feb, 2024
(9 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exservan's drug page


2. Libervant

Libervant is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11273131 Pharmaceutical compositions with enhanced permeation 18 Jun, 2038
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Libervant's drug page


3. Zuplenz

Zuplenz is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9095577 Stabilized amine-containing actives in oral film compositions 13 Jul, 2030
(5 years from now)
Active
US8580830 Non-mucoadhesive film dosage forms 23 Nov, 2029
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zuplenz's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List